Latest Biotech News

Worldwide Clinical Trials agreed to acquire Catalyst Clinical Research in a deal that continues private‑equity‑backed consolidation among contract research organizations (CROs). The acquisition...

Researchers published a next‑generation CAR‑T design that selectively leverages tumor features and microenvironmental cues to improve therapeutic specificity and efficacy. The study outlines...

A Nature Communications paper described a Granzyme B‑mimetic nanozyme packaged in targeted nanovesicles that induces apoptosis in cancer cells. The nanozyme architecture mimics the protease...

The SPARK multi‑cohort Phase II trial reported activity for the combination of sitravatinib and tislelizumab in locally recurrent or metastatic triple‑negative breast cancer (TNBC). The single‑arm...

A Phase I trial tested allogeneic natural killer (NK) cell infusions in patients with recurrent hepatocellular carcinoma (HCC) after liver transplantation and reported signals of safety and...

AnswersNow closed a $40 million Series B led by HealthQuest Capital to expand access to autism therapy via its digital platform. The funding will support scaling clinician networks, technology...

Lead: The multicohort SPARK phase II study reported tumor responses from the combination of sitravatinib and tislelizumab in patients with locally recurrent or metastatic triple-negative breast...

Lead: A phase I study evaluating adoptive natural killer (NK) cell infusions for recurrent hepatocellular carcinoma (HCC) after liver transplantation reported tolerability and preliminary...

Lead: Researchers disclosed a next‑generation CAR‑T engineering approach that programs T cells to sense and exploit tumor-specific features rather than relying solely on single-antigen...

Lead: A Nature Communications study introduced a Granzyme B‑mimetic nanozyme delivered in engineered nanovesicles that selectively induces apoptosis in cancer cells in preclinical models. Authors...

Lead: Two complementary reports from Ma et al. used transcriptome‑wide association study (TWAS) methods to nominate novel causal genes linked to diabetic nephropathy, expanding the genetic map of...

Lead: Bloomberg reported that Qiagen is evaluating strategic options, including a potential sale, after talks with multiple potential buyers and advisers. Market analysts and sources cited renewed...

Lead: STAT reported criticisms around the FDA’s recently proposed “plausible mechanism pathway,” a regulatory concept intended to streamline approval of personalized, small‑batch gene‑editing...

Lead: AnswersNow closed a $40 million Series B led by HealthQuest Capital, with participation from Left Lane Capital and Owl Ventures, to expand access to autism therapy via its telehealth...

Lead: A team led by Laura Osanno published an analysis in Annals of Hematology examining the toxicity‑to‑efficacy ratio of venetoclax in hematologic malignancies, aiming to predict which patients...

Lead: A preclinical study by Yang et al. described KC1036, a novel small molecule candidate that demonstrated anti‑tumor activity in Ewing sarcoma models and revealed mechanistic insights into its...

Researchers published in Nature Communications (2026) report a Granzyme B-mimetic nanozyme packaged in a targeted nanovesicle that selectively induces cancer-cell death. The team describes...

A new study outlines next-generation CAR-T cell designs that exploit tumor-specific features to increase selectivity and antitumor activity. Researchers describe modular CAR constructs that sense...

Phase II SPARK trial results show objective responses when the tyrosine-kinase inhibitor sitravatinib is combined with the anti–PD-1 antibody tislelizumab in patients with locally recurrent or...

A phase I study reports that adoptive infusion of natural killer (NK) cells is feasible and shows preliminary signals in patients with recurrent hepatocellular carcinoma after liver...